健信生物 | 核心产品II/III期临床研究实现首例入组

A Milestone: First Patient Dosed

in Phase II/III Trial for Core Asset

On October 17, 2025, L&L Bio (Shanghai/Ningbo) successfully enrolled the first patient in its Phase II/III clinical trial (Registration No.: CTR20253433/NCT07177716) investigating the PD-1/TIM-3 bispecific antibody LB1410, developed independently by the company, in combination with lenvatinib ± LB4330 for the treatment of immune-resistant cervical cancer. 

The study is led by renowned gynecologic oncology expert Professor Wu Xiaohua as the Leading Principal Investigator (Leading PI) and will be conducted across multiple research centers nationwide to comprehensively initiate patient recruitment and enrollment.

This milestone event marks a critical step for L&L Bio in overcoming tumor immune resistance and signifies the company’s advancement to a new stage.